should we transplant or not in frontline therapy for mcl?
Published 5 years ago • 99 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
3:10
is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for mcl?
-
1:00
the role of transplant in mcl in the era of cellular therapy
-
0:55
investigating the impact of frailty on outcomes of patients with aml
-
2:13
transplant and car-t for relapsed mcl
-
3:56
treatment approaches for patients with tp53-mutated mcl
-
3:44
current treatment options and emerging strategies in mcl
-
2:21
frontline therapy and the role of high-dose consolidation in mantle cell lymphoma
-
1:51
the future of all treatment: moving away from stem cell transplantation
-
2:04
autologous transplantation followed by maintenance vs maintenance alone in patients with mcl
-
10:25
key highlights in nhl: updates in mcl, the role of transplantation, and novel bispecific antibodies
-
4:59
frontline treatment of transplant-ineligible mm: a changing landscape
-
2:23
management of newly diagnosed patients with multiple myeloma not eligible for transplantation
-
8:57
outcomes of sct in t-all and t-lbl
-
1:13
efficacy of transplantation in hl
-
0:43
when might a transplant be considered in mds? #aml
-
3:15
using targeted therapies to optimize transplant outcomes in aml
-
1:43
updates on the use of bispecific antibodies in mcl & the need for more studies in this space
-
3:21
current news in mcl - allogeneic transplants
-
2:40
the current standard of care in mantle cell lymphoma